Anavex Life Sciences Corp. AVXL
At closeNov 4, 2026, 4:02 PM EST
After hours · Nov 4, 4:02 PM ET
- YTD
- -64.61%
- 1 year
- -83.13%
- Market cap
- 116.80M
- EPS (ttm)
- -0.14
- Shares out
- 84.80M
- Forward P/E
- -17.25
- YTD return
- -64.61%
- 1-year return
- -83.13%
- Volume
- 927.74K
- Avg volume
- 1.02M
- Open
- 1.24
- Previous close
- 1.20
- Day's range
- 1.22 – 1.29
- 52-week range
- 1.13 – 7.60
- Beta
- 0.60
- Analysts
- Strong Buy
- Price target
- 35.47 (+2715.3%)
5D -0.04 (-3.08%)
Key statistics
- Enterprise value
- 593.03M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 7.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -19.06M
- Total cash
- 138.76M
- Total debt
- 0
- Return on equity
- -30.03%
- Short % of float
- 23.96%
- 50-day average
- 7.73
- 200-day average
- 5.65
Analyst view
Consensus: strong buy
- Target (low)
- 15.00
- Target (mean)
- 35.47
- Target (high)
- 46.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.19.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 26, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 25, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | EF Hutton | main | Buy | Buy |
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anavex.com
News
AVXL EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026 
Kaplan Fox Notifies Investors of Anavex Life Sciences Corp. (AVXL) of the Lead Plaintiff Deadline on November 30, 2026 
Anavex Life Sciences Corp. Investors Seeking Lead Plaintiff Role Have Until November 30th to Contact Bragar Eagel & Squire, P.C. 
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines – AVXL 
ANAVEX DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL 
ANAVEX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL 
DEADLINE ALERT for Fluence Energy, Inc. (FLNC), Qfin Holdings, Inc. (QFIN), Endava plc (DAVA), and Anavex Life Sciences Corp. (AVXL): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions 
Bronstein, Gewirtz & Grossman LLC Urges Anavex Life Sciences Corp. Investors to Act: Class Action Filed Alleging Investor Harm 
Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors 
Deadline Alert: Anavex Life Sciences Corp. Investors Have Until November 30, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors
Your note
Sign in to keep a note on AVXL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONHAUSER PETER D.O. | Director | Purchase | Jun 13, 2024 | 5,000 |
| MISSLING CHRISTOPHER U | Chief Executive Officer | Sale | Mar 27, 2024 | 1,250,210 |
| THOMAS STEFFEN PHD | Director | Purchase | May 14, 2024 | 5,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.95% | 6,740,696 | 73.27M | Sep 29, 2024 |
| Vanguard Group Inc | 5.59% | 4,740,171 | 51.53M | Sep 29, 2024 |
| State Street Corporation | 3.62% | 3,065,947 | 33.33M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.22% | 1,883,199 | 20.47M | Sep 29, 2024 |
| NWAM LLC | 1.07% | 910,476 | 9.90M | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.98% | 830,624 | 9.03M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.99% | 2,534,500 | 27.55M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.30% | 1,946,169 | 21.15M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.89% | 1,604,415 | 17.44M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.57% | 1,331,918 | 14.48M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.88% | 746,316 | 8.11M | Aug 30, 2024 |
| iShares Biotechnology ETF | 0.69% | 581,949 | 6.33M | Oct 30, 2024 |